JNJ vs SYRE
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. SYRE: Spyre Therapeutics is developing next-generation, extended half-life antibodies and combination therapies aimed at redefining the standard of care for inflammatory bowel disease and immune-mediated conditions.
Side-by-side fundamentals
| Metric | JNJ | SYRE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $256.48 | $79.90 | |
| Market cap | $618.1B | $7.0B | |
| P/E as of 2026-10-08 | 29.74 | n/a | |
| Net margin FY2025, SEC XBRL | +28.5% | n/a | |
| Gross margin FY2025, SEC XBRL | +67.9% | n/a | |
| ROE FY2025, SEC XBRL | +32.9% | -21.7% | JNJ higher |
| ROA FY2025, SEC XBRL | +13.5% | -20.0% | JNJ higher |
| Debt / equity as of 2026-09-02 | 0.58 | 0.00 | SYRE lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +6.2% | n/a | |
| Dividend yield as of 2026-09-02 | +2.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | 0 | JNJ higher |
| Beta as of 2026-09-02 | -0.02 | 1.71 | |
| 1-year return as of 2026-10-08 close | +35.2% | +351.9% | SYRE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.